Viatris Inc. (VTRS)
Viatris Inc. (VTRS) BofA Securities 2025 Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) BofA Securities 2025 Healthcare Conference May 13, 2025 8:00 PM ET Company Participants Doretta Mistras - CFO Philippe Martin - Chief R&D Officer Conference Call Participants Jason Gerberry - BofA Securities Jason Gerberry Keep going here at the BofA Annual Healthcare Conference, and our last company presenter of the day, Viatris. Joining us is Doretta Mistras, Chief Financial Officer; and Philippe Martin, Chief R&D Officer.
Viatris Q1 Earnings and Revenues Beat Estimates, Stock Gains
VTRS Q1 earnings and sales beat estimates. Brands business continues to perform well backed by expansion of portfolio.
Viatris (VTRS) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Viatris (VTRS) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Viatris (VTRS) Beats Q1 Earnings and Revenue Estimates
Viatris (VTRS) came out with quarterly earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.67 per share a year ago.
Unveiling Viatris (VTRS) Q1 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Viatris (VTRS) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Viatris Q1 Earnings Release: What's in Store for the Stock?
VTRS' Q1 results are likely to gain from new product launches in all major geographies.
Analysts Estimate Viatris (VTRS) to Report a Decline in Earnings: What to Look Out for
Viatris (VTRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Viatris to Pay $335 Million for Settlement of Opioid-Related Claims
VTRS has reached an agreement of $335 million to resolve opioid-related claims by states, local governments, and tribes against it and certain of its subsidiaries.
Viatris to pay up to $335 million to resolve opioid-related claims
Viatris said on Monday it would pay up to a maximum of $335 million over nine years as part of a nationwide settlement to resolve opioid-related claims against the drugmaker.
Viatris Inc. (VTRS) Barclays 27th Annual Global Healthcare Conference (Transcript)
Viatris Inc. (NASDAQ:VTRS ) Barclays 27th Annual Global Healthcare Conference Call March 11, 2025 2:00 PM ET Company Participants Scott Smith - Chief Executive Officer Doretta Mistras - Chief Financial Officer Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good afternoon, everyone. Thank you all for joining us at the Barclays Healthcare Conference, continuing our spec pharma session for the day.
Viatris: A Unique S&P 500 'Fallen Angel' With Intriguing Potential
Viatris emerged from Pfizer's merger with Mylan and Upjohn, trading since 2020, with a market cap of $11 billion. Despite the recent stock plunge, VTRS trades at under 5x trailing earnings, making it an intriguing "dog collar" investment opportunity. The stock boasts strong profitability (A+) and valuation (A), but recent earnings miss raises concerns about future performance.
Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings
The headline numbers for Viatris (VTRS) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
